Abiopharma

ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Qiagen N.V. - QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

Innate Pharma - Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

General Announcement: ISSUANCE OF SHARES PURSUANT TO EXERCISE OF WARRANTS

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: iTeos Therapeutics, Inc. - Common Stock.

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: iTeos Therapeutics, Inc. - Common Stock.

NASDAQ traded attribute type Security_Name was changed. Previous value: iTeos Therapeutics, Inc. - Common Stock. New value: iTeos Therapeutics, Inc. - Common Stock.

XBRL 30 June 2025 filed with the SEC

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

General Announcement: RECEIPT OF LETTERS OF CLAIM

How to Use Your iPhone As A Scanner

Rocket Money (2025 Guide)